Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Chest MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.N Engl J Med. 2018; 379: 1612-1620
- Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.Am J Respir Crit Care Med. 2018; 197: 1433-1442
- Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.Proc Am Thorac Soc. 2007; 4: 387-398
- Discovery of N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally Bioavailable CFTR potentiator.J Med Chem. 2014; 57: 9776-9795
- Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator.iScience. 2021; 24: 102542
- A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.N Engl J Med. 2011; 365: 1663-1672
- Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.J Cyst Fibros. 2014; 13: 674-680
- Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.Lancet Respir Med. 2015; 3: 524-533
- Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.J Cyst Fibros. 2014; 13: 29-36
- Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).Lancet Respir Med. 2014; 2: 902-910
- Real-world long-term ivacaftor for cystic fibrosis in France: clinical effectiveness and healthcare resource utilization.Pulm Ther. 2021; https://doi.org/10.1007/s41030-021-00158-5
- Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries.J Cyst Fibros. 2020; 19: 68-79
- Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.Am J Respir Crit Care Med. 2015; 192: 836-842
- Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.Am J Respir Crit Care Med. 2014; 190: 175-184
- Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.J cystic fibrosis. 2021; 20: 213-219
- Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.Chest. 2009; 135: 1610-1618
- Longitudinal trends in real-world outcomes after initiation of ivacaftor. A cohort study from the cystic fibrosis registry of Ireland.Ann Am Thorac Soc. 2019; 16: 209-216
- Pharmacological modulation of ion channels for the treatment of cystic fibrosis.J Exp Pharmacol. 2021; 13: 693-723
- Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.JCI Insight. 2020; 5https://doi.org/10.1172/jci.insight.139983
- Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.N Engl J Med. 2019; 381: 1809-1819
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.Lancet. 2019; https://doi.org/10.1016/S0140-6736(19)32597-8
- A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.Am J Respir Crit Care Med. 2021; 203: 1522-1532
- Elexacaftor-tezacaftor-ivacaftor (Trikafta) prescribing information. Vertex Pharmaceuticals, Incorporated, 2019
- Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.N Engl J Med. 2017; 377: 2013-2023
- Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis.N Engl J Med. 2017; 377: 2024-2035
- Triple therapy for cystic fibrosis Phe508del–gating and –residual function genotypes.N Engl J Med. 2021; 385: 815-825
- Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease.J Cystic Fibrosis. 2020; 19: 344-354
- Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease.Am J Respir Crit Care Med. 2021; 204: 64-73
- Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease.Eur Respir J. 2021; 57: 2003079
- Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease.J Cyst Fibros. 2021; 20: 768-771
- Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation.J Cyst Fibros. 2021; 20: 402-406
- Triple Therapy for Cystic Fibrosis with a Phe508del CFTR Mutation.N Engl J Med. 2020; 382: 684
- Transparency and diversity in cystic fibrosis research.Lancet. 2020; 396: 601
- Elexacaftor-tezacaftor-ivacaftor (Trikafta) prescribing information. Vertex Pharmaceuticals, Incorporated, 2021
- Testicular pain following initiation of elexacaftor/tezacaftor/ivacaftor in males with cystic fibrosis.J Cystic Fibrosis. 2020; 19: e39-e41
- Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis.J Cystic Fibrosis. 2021; 20: 506-510
- Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: a two center case series.J Cyst Fibros. 2021; 20: 399-401
- Impact of CFTR therapy on chronic rhinosinusitis and health status: Deep Learning CT Analysis and patient reported outcomes.Ann Am Thorac Soc. 2021; https://doi.org/10.1513/AnnalsATS.202101-057OC
- Clinical effectiveness of elexacaftor/Tezacftor/ivacaftor in people with cystic fibrosis.Am J Respir Crit Care Med. 2021; https://doi.org/10.1164/rccm.202108-1986OC
- Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.Am J Respir Crit Care Med. 2013; 187: 1219-1225
- Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.Lancet Respir Med. 2016; 4: 107-115
- An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5years (KLIMB).J cystic fibrosis. 2019; 18: 838-843
- Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.Lancet Respir Med. 2018; 6: 545-553
- Ivacaftor in infants aged 4 to <12 Months with cystic fibrosis and a gating mutation: results of a 2-Part Phase 3 clinical trial.Am J Respir Crit Care Med. 2020; https://doi.org/10.1164/rccm.202008-3177OC
- The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review.Arch Dis Child. 2018; 103: 68-70
- Growth in Prepubertal children with cystic fibrosis treated with ivacaftor.Pediatrics. 2017; 139https://doi.org/10.1542/peds.2016-2522
- Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.Lancet Respir Med. 2013; 1: 630-638
- Changes in lung clearance index in preschool-aged patients with cystic fibrosis treated with ivacaftor (GOAL): a clinical trial.Am J Respir Crit Care Med. 2018; 198: 526-528
- Ivacaftor and airway inflammation in preschool children with cystic fibrosis.Am J Respir Crit Care Med. 2021; 204: 605-608
- Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor.Paediatr Respir Rev. 2020; https://doi.org/10.1016/j.prrv.2020.04.003
- Pancreatic insufficiency converted to pancreatic sufficiency with ivacaftor.Pediatr Pulmonol. 2019; 54: 1654
- Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use.Pediatr Pulmonol. 2019; 54: E16-E18
- Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor.Pediatr Pulmonol. 2020; 55: 3381-3383
- Sustained recovery of exocrine pancreatic function in a teenager with cystic fibrosis treated with ivacaftor.Pediatr Pulmonol. 2020; 55: 2493-2494
- Partial restoration of pancreatic function in a child with cystic fibrosis.Lancet Respir Med. 2016; 4: e21-e22
- Appearance of pancreatic sufficiency and discontinuation of pancreatic enzyme replacement therapy in children with cystic fibrosis on ivacaftor.Ann Am Thorac Soc. 2021; 18: 182-183
- Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials.Am J Respir Crit Care Med. 2006; 174: 787-794
- Children and young adults with CF in the USA have better lung function compared with the UK.Thorax. 2015; 70: 229-236
- Pseudomonas aeruginosa reduces VX-809 stimulated F508del-CFTR chloride secretion by airway epithelial cells.PLoS One. 2015; 10: e0127742
- Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis.J Cyst Fibros. 2021; 20: 612-617
- Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations.J Cyst Fibros. 2017; 16: 36-40
- Lung function in infants with cystic fibrosis Diagnosed by newborn screening.Am J Respir Crit Care Med. 2008; 178: 1238-1244
- Infection, inflammation, and lung function decline in infants with cystic fibrosis.Am J Respir Crit Care Med. 2011; 184: 75-81
- In Utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis.Sci translational Med. 2019; 11: eaau7531
- Ivacaftor (Kalydeco) prescribing information. Vertex Pharmaceuticals, 2020
- Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy.J Cyst Fibros. 2021; 20: 835-836
- Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey.J Cyst Fibros. 2020; 19: 521-526
- Long-term ivacaftor in people aged 6 Years and older with cystic fibrosis with ivacaftor-responsive mutations.Pulm Ther. 2020; 6: 303-313
- Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: interim Results of an Open-Label Phase 3 Clinical Trial.Am J Respir Crit Care Med. 2021; 203: 381-385
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
